Angiotensin II: A devious activator of mineralocorticoid receptor-dependent gene expression

Circulation Research

Volumn 96, Issue 6, 2005, Pages 610-611

  Blaxall, Burns C ^a   Miano, Joseph M ^a   Berk, Bradford C ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Angiotensin II; Mineralocorticoid receptor; Spironolactone

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ESTROGEN RECEPTOR; FARNESOID X RECEPTOR; HYDROCORTISONE; LIVER X RECEPTOR; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE;

ADRENAL CORTEX; AGING; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CALCIFICATION; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL DIFFERENTIATION; DATA ANALYSIS; DNA MICROARRAY; EDITORIAL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HORMONE RELEASE; HORMONE SYNTHESIS; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION; VASCULAR DISEASE; VASCULAR FIBROSIS; VASCULAR SMOOTH MUSCLE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; AGING; ALDOSTERONE; ANGIOTENSIN II; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, MINERALOCORTICOID; TRANS-ACTIVATION (GENETICS);

EID: 16444378401     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000162163.75564.8b     Document Type: Editorial

References (21)

1. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96:643-650.
2. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol. 1984;246:H608-H614.
3. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappa activation in angiotensin II-induced cardiac injury. Hypertension. 2001;37:787-793.
4. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
5. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269: 24316-24320.
6. Saito Y, Berk BC. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol. 2001; 33:3-7.
7. Konishi A, Berk BC. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J Biol Chem. 2003;278:35049-35056.
8. Ushio-Fukai M, Griendling KK, Becker PL, Hilenski L, Halleran S, Alexander RW. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:489-495.
9. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45(Suppl):773-779.
10. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation. 2002; 105:2296-2302.
11. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
12. Streb JW, Miano JM. Retinoids: pleiotropic agents of therapy for vascular diseases? Curr Drug Targets Cardiovasc Haematol Disord. 2003;3: 31-57.
13. Boukhtouche F, Mariani J, Tedgui A. The "CholesteROR" protective pathway in the vascular system. Arterioscler Thromb Vasc Biol. 2004; 24:637-643.
14. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002;90:3F-6F.
15. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003;17:985-993.
16. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA. 2004;101:3668-3673.
17. Campos AH, Zhao Y, Pollman MJ, Gibbons GH. DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res. 2003;92: 111-118.
18. Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005;45:163-169.
19. Abdalla S, Lother H, Langer A, El Faramawy Y, Quitterer U. Factor XIIIA Transglutaminase crosslinks AT(1) receptor dimers of monocytes at the onset of atherosclerosis. Cell. 2004;119:343-354.
20. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42:49-55.
21. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109:2213-2220.